Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial is a phase 2, randomised interventional study registered as NCT05673148 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 146 participants, started 2023-10-09 and due to reach its primary completion in 2028-07-03. Interventions recorded: Stereotactic Ablative Radiotherapy; Resection; Microwave Ablation; Chemotherapy; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography. Conditions listed: Metastatic Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8; Oligometastatic Colorectal Carcinoma. Primary outcome: Overall Survival (OS). Colorectal eligibility wording from the registry: "* PRE-REGISTRATION (STEP 0): Pathologically proven diagnosis of metastatic colorectal adenocarcinoma with metastases (biopsy from primary tumor or metastatic site is acceptable)". Sites: Canada, United States. No results are recorded here; the registry entry is the source.